Saptak Chem (SCBL) Q1 FY27's Loss Narrows to ₹5 Lakh on Zero Revenue
Saptak Chem and Business reported a net loss of ₹0.05 crore for Q1 FY27, a sequential improvement, while revenue remained absent for another quarter.
Saptak Chem and Business reported a Q1 FY27 net loss of ₹0.05 crore, an improvement from the prior quarter. The company generated zero revenue, a state that has persisted for years, as new leadership takes the helm.
For Saptak Chem and Business, the first quarter of FY27 was another period defined by what did not happen. The chemical trading company reported zero revenue for the quarter ended June 2026, continuing a multi-year streak with no sales. The only movement was a smaller loss, which narrowed sequentially but offered no sign of a business revival.
The numbers tell a story of stagnation. Revenue has been nil for five consecutive quarters. The net loss for Q1 FY27 stood at ₹0.05 crore, an improvement from the ₹0.12 crore loss in Q4 FY26, according to the company's filings. Year-on-year, the loss also narrowed from ₹0.06 crore.
Revenue (₹ Cr)
Profit (₹ Cr)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Period | Jun 2026 | Mar 2026 | Jun 2025 |
| Revenue (₹ Cr) | 0.00 | 0.00 | 0.00 |
| Profit (₹ Cr) | -0.05YoY +17% | -0.12 | -0.06 |
The cost of standing still
The reduced loss came from lower quarterly expenses, which fell to ₹0.05 crore from ₹0.12 crore in the prior quarter, as noted by StockWatch. With no revenue, these expenses—primarily employee benefits and other administrative costs—represent the entire cash burn to maintain corporate existence. A MarketsMojo report from May 2026 stated the company has been effectively dormant since FY19.
Funding this burn relies on external capital. The company's cash flow statement for FY26, cited by StockFin.ai, showed cash from financing activity of ₹1.34 crore, which included proceeds from a preferential issue of warrants. This inflow funded operations, as cash from operations was negative ₹1.09 crore.
A balance sheet of absence
The company's financial structure is fragile. Despite a current ratio of 425, a figure that suggests strong liquidity, the underlying assets are minimal. The balance sheet as of March 2026 showed total assets of just ₹1.15 crore against a negative net worth, according to StockFin.ai. This high ratio is a mathematical artifact of tiny current assets against even tinier current liabilities, not operational strength.
Leadership is in transition, but a plan is absent. The company appointed Mr. Ayush Tated as Managing Director, and shareholders confirmed his role at the 47th AGM in August 2026, as reported by ScanX. However, management has provided no forward-looking guidance or revival strategy in recent disclosures reviewed by StockFin.ai.
Key Points
- Saptak Chem reported zero revenue for Q1 FY27, continuing a multi-year trend with no core business activity.
- The net loss narrowed to ₹0.05 crore from ₹0.12 crore in Q4 FY26, driven solely by lower administrative expenses.
- The company survives on financing inflows, with a recent preferential warrant issue funding operations.
- New management is in place, but no concrete business revival plan has been communicated to investors.
- The balance sheet shows minimal assets and negative net worth, with a high current ratio reflecting negligible size rather than health.
Hexa Perspective
This quarter confirms Saptak Chem remains a corporate shell with no operating business. The narrowing loss is a minor accounting detail, not a turnaround. The appointment of a new MD is a governance formality until it is paired with a credible strategy to generate revenue.
Investors are left weighing governance continuity against fundamental absence. The stock's 3-year return of over 1,200% is disconnected from these realities, trading on speculative momentum alone. For the narrative to change, the next quarter must show the first rupee of revenue in years—a bar the company has consistently failed to clear.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.